Quince Therapeutics Inc
NASDAQ:QNCX
Operating Margin
Quince Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Quince Therapeutics Inc
NASDAQ:QNCX
|
73.7m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.2B USD |
31%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
154.1B USD | N/A | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.2B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
145.5B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.9B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
109.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
64.1B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
61.1B USD |
-7%
|
Quince Therapeutics Inc
Glance View
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing precision therapeutics targeting debilitating and rare diseases. The firm has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The firm's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Quince Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet